Chagas disease is endemic in many parts of Latin America and is a particularly serious problem among the rural poor, where it is estimated that 6 to 7 million people are infected with the protozoan parasite Trypanosoma cruzi (T. cruzi). The disease has also become a global health problem, with several hundred thousand infected people among immigrants, mainly in the United States and Europe. There is currently no vaccine against Chagas disease. Given the immunological complexity and long-term nature of this infection, progress in this area is uncertain. T. cruzi is an obligate intracellular parasite with an extremely wide mammalian host range and can infect most nucleated cells. In humans, the initial acute phase of the disease lasts 4-6 weeks and is associated with significant parasitemia and infection of most tissues and organs. However, the symptoms are usually mild and non-specific, with short-term fever and muscle pain; most people do not realize they are infected. In some cases, the disease may be more serious, especially in children, whose death may be caused by myocarditis or encephalopathy.
Although it was first discovered more than a century ago, there are currently only two drugs available to treat this disease, and the results of the first clinical trial in 40 years are unremarkable. There is an urgent need to develop new drugs for the treatment of Chagas disease. This requires a better understanding of the parasite infection process and standardization of animal models designed for the development of drugs for Chagas disease. Such measures will improve the comparison of generated data and the predictability of test hypotheses and models designed for translation to human disease.
Creative Diagnostics believes that animal models are very useful for studying human diseases because there are hundreds of pathogens that can affect humans and animals. The use of laboratory animals in biomedical research is a key factor in the development of new prevention methods and the treatment of infectious and non-communicable diseases. Our experienced professional team can provide standard in vivo prediction models of Chagas disease for drug discovery and treatment efficacy studies that need to be developed and validated.
Creative Diagnostics is a full-service contract research organization specializing in microbiology and preclinical infectious disease research. The correct animal model provides unlimited possibilities for drug discovery and human health advancement. At Creative Diagnostics, we believe that providing clients with the best animal model solutions is the most effective way to promote key research from creativity to reality. We guarantee that the animal models required in research are strictly regulated to ensure responsible, ethical, and humane treatment.